Cutler Group LP Iveric Bio, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 18, 2023	SELL	$26.24 - $39.63 $23,616 - $35,667	-900 Reduced 90.0%	100 $1,000
Q1 2023 May 01, 2023	SELL	$18.67 - $24.56 $141,892 - $186,656	-7,600 Reduced 88.37%	1,000 $0
Q4 2022 Feb 07, 2023	SELL	$17.24 - $23.95 $399,967 - $555,640	-23,200 Reduced 72.96%	8,600 $1,000
Q3 2022 Oct 25, 2022	BUY	$9.4 - $18.59 $298,920 - $591,162	31,800 New	31,800 $44,000
Q2 2022 Aug 04, 2022	SELL	$9.12 - $18.9 $272,688 - $565,110	-29,900 Closed	0 $0

Q1 2022 Apr 14, 2022	BUY	$12.15 - $16.83 $348,705 - $483,020	28,700 Added 2391.67%	29,900 $49,000
Q4 2021 Jan 18, 2022	SELL	$13.83 - $18.78 $757,884 - $1.03 Million	-54,800 Reduced 97.86%	1,200 $3,000
Q3 2021 Oct 26, 2021	BUY	$7.07 - $17.5 $395,920 - $980,000	56,000 New	56,000 $88,000
Q2 2020 Jul 22, 2020	SELL	$3.06 - $6.6 $4,896 - $10,560	-1,600 Closed	0 $0
Q1 2020 May 07, 2020	SELL	$2.83 - $8.44 $849 - $2,532	-300 Reduced 15.79%	1,600 $0
Q4 2019 Feb 06, 2020	BUY	$0.93 - $8.58 $1,767 - $16,302	1,900 New	1,900 $3,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.